Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis
MarketScreener,
(LSE/NYSE: GSK) today announced that the (FDA) has granted Orphan Drug Designation (ODD) to Benlysta (belimumab), a B-cell…
(LSE/NYSE: GSK) today announced that the (FDA) has granted Orphan Drug Designation (ODD) to Benlysta (belimumab), a B-cell…
Issued: 1 February 2023, London UK for the potential treatment of systemic sclerosis GSK plc (LSE/NYSE: GSK) today announced…
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD…